Abstract. In this paper, an optimal control problem of HIV infection model of delay differential equations is taken into account. Two Optimal controls variables are explored. These optimal control variables represent reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). The existence and uniqueness results for the optimal control pair are established. The optimality system is derived using Pontryagin's Maximum Principle and then solved numerically. Finally, conclusion is drawn. 2010 Mathematics Subject Classifications: 92D25, 49J15, 93D20.
Introduction
HIV stands for human immunodeficiency virus. It is the virus that can lead to acquired immunodeficiency syndrome, or AIDS, if not treated. Unlike some other viruses, the human body can't get rid of HIV completely, even with treatment. HIV attacks the body's immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. No effective cure currently exists, but with proper medical care, HIV can be controlled. But with proper medical care, HIV can be controlled. Mathematical models have evaluated a wide range of different HIV prevention and treatment programmes. Mathematical modeling over the years has been useful in analyzing various diseases dynamics, such as HIV/AIDS, Malaria and Tuberculosis, and also plays an important role in the better understanding of epidemiological patterns for diseases control, as it provides short and long term prediction of diseases incidence. Several mathematical models have been formulated in order to understand the dynamics of HIV infection [6, 9, [13] [14] [15] [16] [19] [20] [21] [22] . These models are utilized to explore optimal chemotherapy treatment to avoid an excessive use of drugs. Indeed, when these drugs are administered in high dose they are toxic to the human body and cause damages. Fister et al. [16] applied optimal control on HIV-1 model and discussed the percentage effect of the chemotherapy on the interaction of the CD4+ T cells with the virus. Similarly, Joshi [12] taken into account two control variables, one for raising the immune system and the other for delaying HIV-1 progression. Garira et al. [4] used two controls strategies which simulate the effect of reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) to integrate drug efficacy. Ghanbari and Farahi [5] obtained optimal control pair for nonlinear delay HIV model with quadratic cost functional by using Fourier series approximation. Recent research work has been focused on optimal control problem of delayed HIV model (see for example [7, 8, 10, 11] ). All these models considered the effect of control strategy on single pathogen virus. Here, we consider the delayed HIV-1 model consists of two types of viruses, that is, pathogen virus and engineered virus. In this paper, we develop the best strategy of treatment; more exactly we seek to search a maximum count of healthy cells with a minimum dose of the administered drugs. To introduce a control to the proposed model, we analyze the interactions of healthy CD4+T cells, single infected CD4+T cells,double infected cells, free virus and recombinant virus: two major categories of anti-retroviral drugs to combat HIV are reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). RTIs prevent new HIV infection by discrupting the conversion of viral RNA into DNA inside of T cells. PIs reduce the number of viruses particles produced by an actively-infected T cells. Hence, if we denote 0 ≤ u 1 (t) < 1 the RTI control variable and 0 ≤ u 2 (t) < 1 the PI control variable equations. These controls are measurable functions satisfying 0 ≤ u j (t) < 1 for j = 1; 2. Thus, the following optimal control problem is formulated.
with initial conditions
Here, x(t), y(t), v(t), z(t) and w(t) denote the densities of uninfected target cells, infected cells, free virus, double infected cells and recombinant viruses at time t, respectively. The transitions between different states are described by the following parameters.
(i) Λ is the recruitment rate of uninfected cells.
(ii) β is an effective contact rate.
(iii) d is the natural mortality rate.
(iv) a stands for death rate of infected cells.
(v) k is the rate of virus production.
(vi) α is the infection rate of pathogen infected cells.
(vii) p is the death rate of pathogen virus.
(viii) q is the death rate of recombinant virus.
(ix) c is the rate of production of double infected cells.
(x) τ can be regarded as the average time for a viral particle to go through the eclipse phase (or average latent period).
Our target is to find the control functions u 1 (t) and u 2 (t) to get the following achievements. (ii) To minimize the cost of treatment, the density of pathogen virus and the density of infected cells.
In order to achieve our target, we construct the following objective functional:
where ρ 1 and ρ 2 are weight constants which balance the size of the optimal conditions and the parameters ξ 1 ≥ 0 and ξ 1 ≥ 0 are established on the benefits and costs of the treatment. These parameters equalize the size of the terms u 1 (t) and u 2 (t) which reflect the severeness of the side effects of the drugs.
To find the basic reproductive number, we follow the techniques presented in [1-3] for the control problem is given by
Clearly, the value of R 0 s decreased by increasing the values of u 1 (t) and u 2 (t). But the infection starts if R 0 > 1. For the system (1), with time delays τ = 0, the disease-free equilibrium always exists.
where,
The recombinant present equilibrium E r (x 2 , y 2 , z 2 , v 2 , w 2 ) is given by
,
We find optimal control functions u ⋆ 1 (t) and u ⋆ 2 (t) such that
where
, is the control set.
Existence of control problem
In this section, we show the existence of the control problem. To do this, first we find the lagrangian of the optimal control problem.
The corresponding Hamiltonian can be defined as
where x τ := x(t − τ ) and v τ := v(t − τ ). This Hamiltonian determines the control functions for the proposed optimal control problem.
To show the existence of optimal pair, we use the idea of Fleming and Rishel in [? ] . Theorem 3.1: For the control problem with the model (1), there always exists
Proof : To prove the existence of optimal control, we will follow [? ] . We see that the set of controls and state variables are nonnegative and nonempty [17] . The optimal system is bounded which determines the compactness needed for the existence of the optimal control. Also, the state system is bounded by a linear function in the state and control variables. Therefore, the control set U is convex and closed. Using the boundedness of the solution, we see that the RHS of the integrand of the objective functional is concave on U . Finally, we can prove that there exist constants h 1 , h 2 > 0, and η > 1 such that the integrand L(x(t), w(t), u 1 (t), u 2 (t)) of the objective functional satisfies
Thus, conclude that there exists an optimal control. Next, we use Pontryagin's Maximum Principle [18] to discuss the following theorem. Theorem 3.2: For the optimal control u ⋆ 1 (t), u ⋆ 2 (t) and solutions x ⋆ (t), y ⋆ (t), z ⋆ (t), v ⋆ (t), and w ⋆ (t) of the corresponding state system (1), there are adjoint variables λ i (t), i =Proof : Using Pontryagin's Minimum Principle presented in [18] , we get the following system of adjoint variables
By using the property of control space, the equations (9) and (10) can be written as 
The above two equations for u ⋆ 1 (t) and u ⋆ 2 (t) can be written as (using compact notation)
In this section, we present numerical results of the optimal control problem. We solve the state system forward in time by Runge-Kutta fourth order scheme and the adjoint system by backward fourth order scheme. We illustrate a case for two different values for 50-day treatment schedule. Some of the parameter values are considered from real data (see for more detail references [1-3]) and some are estimated. The given figures (1 − 6) are the simulation results of our proved theoretical results. We can make some decisions on the potency of drug therapies based on the densities of uninfected cells, infected cells, double infected cells, free virus and recombinant virus. We considered 70-day treatment and the following were observed. After some time, the number of T cells consistently increased throughout the treatment period, the actively infected cells and the viral load all decreased till the end of the treatment period. Fig 1  represents the concentration of T cells during the proposed treatment period. The T cell population decreases up to some time, but increases after treatment. The concentration of T cells increases in a logistic way. However, for a higher systemic cost, the T cell population increases at a slower rate. With both weight factors, the maximal chemotherapy is given for about the 20 days. Therefore, for the higher systemic cost, the optimal chemotherapy given produces a lower T cell concentration and a higher virus concentration. (Fig 2) shows that the number of infected cells approaches to a very small number after treatment, 
Concluding Remarks
In this work, we have presented a single delayed HIV-1 mathematical model with two controls variables. Although, there is no effective therapy for HIV infection but different treatments are available to block off the development of the virus production in the body and maintain balance between the virus and the defense system. These treatments can cause heavy side effects such as nausea, diarrhea, fatigue, etc. Moreover, the cost of treatment is beyond reach of many infected patients. Hence, we introduced an optimal therapy in order to minimize the cost of treatment, reduce the viral load and improve the immune response. We used two controls which measure the efficacy of reverse transcriptase and protease inhibitors, respectively. In addition, we discussed an efficient numerical method based on optimal control to identify the best treatment strategy of HIV infection in order to block new infection, increase the density of recombinant viruses and minimize the number of pathogen viruses by using drug therapy with minimum side effects. The numerical simulations have shown that the viral load drops off after treatment while the densities of CD4+ cells and recombinant virus increases.
